Ovarian cancer remains one of the deadliest gynecological cancers worldwide. This review summarizes recent findings on its epidemiology, diagnosis, staging, treatment, and future directions. Despite scientific progress, ovarian cancer is still often detected at advanced stages due to vague symptoms and lack of effective early screening. This paper draws from recent studies, guidelines, and databases to outline current trends, molecular mechanisms, and diagnostic methods such as imaging and biomarkers. Surgery combined with platinum-based chemotherapy remains standard care, while genetic profiling and PARP inhibitors mark advances in personalized treatment. Challenges like drug resistance, healthcare disparities, and the lack of early detection persist, urging development of better diagnostic tools and broader access to targeted therapies and immunotherapy. Future research should focus on simple screening tests, deeper understanding of tumor biology, and universal genetic testing availability. Although management has improved, timely detection and individualized treatment are vital. Continued research and better healthcare infrastructure are key to improving survival and quality of life for ovarian cancer patients.
Woźniak et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: